Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413335 · ClinicalTrials.gov registry record · NA
Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT00413335 is a NA study that has completed, run by Yale University. The registered enrollment target is 21 participants.
The verdict
NCT00413335, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
Interventions
- DRUG Placebo
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413335
The ClinicalTrials.gov registry entry for NCT00413335 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00413335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413335 about?
NCT00413335 is a clinical study titled "Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth". The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
What is the current status of trial NCT00413335?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2005-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00413335?
The interventions under investigation include: Placebo (DRUG), Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00413335?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.